Pliant Therapeutics, a renowned late-stage biotechnology company specializing in the development of innovative treatments for fibrotic diseases, made substantial advancements in its Bexotegrast Program during the European Association for the Study of the Liver (EASL) International Liver Congress. The event, held from June 5-8, 2024, witnessed the company s announcement of two significant poster presentations, one of which was a late-breaker, showcasing compelling evidence of its potential therapeutic breakthrough.Pliant Therapeutics, listed on the Nasdaq as PLRX, has emerged as a leader in the sector, committed to resolving the challenges posed by fibrotic diseases. With their state-of-the-art approach, the ...
Pliant Therapeutics Presents Success of Bexotegrast Program in Treating Fibrotic DiseasesSOUTH SAN FRANCISCO, Calif., May 21, 2024 - Pliant Therapeutics, a leading clinical-stage biotechnology company specializing in the discovery and development of revolutionary therapeutics for fibrotic diseases, recently presented groundbreaking clinical and preclinical data at the American Thoracic Society (ATS) International Conference held from May 17-22, 2024. The data showcased the promising potential of their innovative drug, bexotegrast (PLN-74809), in tackling fibrotic diseases.Fibrotic diseases occur as a result of abnormal and persistent scarring of vital organs, leading to their malfunction and increased morbid...
IPF is a chronic, progressive form of lung disease characterized by fibrosis, or scarring, of the lung tissues. The development of excessive collagen, a key component of scar tissues, contributes to the progression of IPF. The promising results from the Phase 2a trial positions Pliant Therapeutics Bexotegrast as a potential therapy in reducing lung collagen, crucial in inhibiting the progression of this devastating disease.Headquartered in South San Francisco, California, Pliant Therapeutics is a clinical-stage biotechnology company at the forefront of developing groundbreaking therapeutics for the treatment of fibrotic diseases. This recent development in their narrative puts them further ahead in their pu...
Pliant Therapeutics: Speeding Up Bexotegrast Development for Idiopathic Pulmonary Fibrosis TreatmentIn recent news, Pliant Therapeutics, a clinical-stage biopharmaceutical company specializing in fibrotic diseases, has announced an accelerated development plan for Bexotegrast. This treatment aims to address Idiopathic Pulmonary Fibrosis (IPF), an incurable and potentially fatal fibrotic lung disease. Notably, the plan has been accepted by the European Union and other global health authorities, allowing for a pivotal, adaptive Phase 2b/3 trial. This milestone holds significant promise for both Pliant Therapeutics and patients suffering from IPF.Facts:1. Pivotal Phase 2b/3 trial acceptance:Pliant Therapeutics ...
Sources:
Pliant Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Pliant Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Pliant Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
